These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9158869)

  • 1. Synthesis of N-glyoxylyl peptides and their in vitro evaluation as HIV-1 protease inhibitors.
    Qasmi D; de Rosny E; René L; Badet B; Vergely I; Boggetto N; Reboud-Ravaux M
    Bioorg Med Chem; 1997 Apr; 5(4):707-14. PubMed ID: 9158869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Probing the S1/S1' substrate binding pocket geometry of HIV-1 protease with modified aspartic acid analogues.
    Short GF; Laikhter AL; Lodder M; Shayo Y; Arslan T; Hecht SM
    Biochemistry; 2000 Aug; 39(30):8768-81. PubMed ID: 10913288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A series of penicillin-derived C2-symmetric inhibitors of HIV-1 proteinase: structural and modeling studies.
    Wonacott A; Cooke R; Hayes FR; Hann MM; Jhoti H; McMeekin P; Mistry A; Murray-Rust P; Singh OM; Weir MP
    J Med Chem; 1993 Oct; 36(21):3113-9. PubMed ID: 8230097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, asymmetric synthesis, and evaluation of pseudosymmetric sulfoximine inhibitors against HIV-1 protease.
    Lu D; Sham YY; Vince R
    Bioorg Med Chem; 2010 Mar; 18(5):2037-48. PubMed ID: 20138769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxyethylamine isostere of an HIV-1 protease inhibitor prefers its amine to the hydroxy group in binding to catalytic aspartates. A synchrotron study of HIV-1 protease in complex with a peptidomimetic inhibitor.
    Dohnálek J; Hasek J; Dusková J; Petroková H; Hradilek M; Soucek M; Konvalinka J; Brynda J; Sedlácek J; Fábry M
    J Med Chem; 2002 Mar; 45(7):1432-8. PubMed ID: 11906284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-aided design of novel inhibitors of HIV protease based on a benzodiazepine scaffold.
    Schimer J; Cígler P; Veselý J; Grantz Šašková K; Lepšík M; Brynda J; Rezáčová P; Kožíšek M; Císařová I; Oberwinkler H; Kraeusslich HG; Konvalinka J
    J Med Chem; 2012 Nov; 55(22):10130-5. PubMed ID: 23050738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysine sulfonamides as novel HIV-protease inhibitors: Nepsilon-acyl aromatic alpha-amino acids.
    Stranix BR; Lavallée JF; Sévigny G; Yelle J; Perron V; LeBerre N; Herbart D; Wu JJ
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3459-62. PubMed ID: 16644213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
    Ghosh AK; Kincaid JF; Walters DE; Chen Y; Chaudhuri NC; Thompson WJ; Culberson C; Fitzgerald PM; Lee HY; McKee SP; Munson PM; Duong TT; Darke PL; Zugay JA; Schleif WA; Axel MG; Lin J; Huff JR
    J Med Chem; 1996 Aug; 39(17):3278-90. PubMed ID: 8765511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-strand mimicking macrocyclic amino acids: templates for protease inhibitors with antiviral activity.
    Glenn MP; Pattenden LK; Reid RC; Tyssen DP; Tyndall JD; Birch CJ; Fairlie DP
    J Med Chem; 2002 Jan; 45(2):371-81. PubMed ID: 11784141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A folding inhibitor of the HIV-1 protease.
    Broglia RA; Provasi D; Vasile F; Ottolina G; Longhi R; Tiana G
    Proteins; 2006 Mar; 62(4):928-33. PubMed ID: 16385559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A distinct binding mode of a hydroxyethylamine isostere inhibitor of HIV-1 protease.
    Dohnálek J; Hasek J; Dusková J; Petroková H; Hradilek M; Soucek M; Konvalinka J; Brynda J; Sedlácek J; Fábry M
    Acta Crystallogr D Biol Crystallogr; 2001 Mar; 57(Pt 3):472-6. PubMed ID: 11223536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy.
    Lindberg J; Pyring D; Löwgren S; Rosenquist A; Zuccarello G; Kvarnström I; Zhang H; Vrang L; Classon B; Hallberg A; Samuelsson B; Unge T
    Eur J Biochem; 2004 Nov; 271(22):4594-602. PubMed ID: 15560801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis, stability, antiviral activity, and protease-bound structures of substrate-mimicking constrained macrocyclic inhibitors of HIV-1 protease.
    Tyndall JD; Reid RC; Tyssen DP; Jardine DK; Todd B; Passmore M; March DR; Pattenden LK; Bergman DA; Alewood D; Hu SH; Alewood PF; Birch CJ; Martin JL; Fairlie DP
    J Med Chem; 2000 Sep; 43(19):3495-504. PubMed ID: 11000004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate -- interactions with frequently occurring glutamic acid residue at P2' position of substrates.
    Weber IT; Wu J; Adomat J; Harrison RW; Kimmel AR; Wondrak EM; Louis JM
    Eur J Biochem; 1997 Oct; 249(2):523-30. PubMed ID: 9370363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV.
    Jadhav PK; Ala P; Woerner FJ; Chang CH; Garber SS; Anton ED; Bacheler LT
    J Med Chem; 1997 Jan; 40(2):181-91. PubMed ID: 9003516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cycloalkylpyranones and cycloalkyldihydropyrones as HIV protease inhibitors: exploring the impact of ring size on structure-activity relationships.
    Romines KR; Morris JK; Howe WJ; Tomich PK; Horng MM; Chong KT; Hinshaw RR; Anderson DJ; Strohbach JW; Turner SR; Mizsak SA
    J Med Chem; 1996 Sep; 39(20):4125-30. PubMed ID: 8831779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Syntheses of HIV-protease inhibitors having a peptide moiety which binds to GP120.
    Asagarasu A; Uchiyama T; Achiwa K
    Chem Pharm Bull (Tokyo); 1998 Apr; 46(4):697-703. PubMed ID: 9579045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. X-ray structure of HIV-1 protease in situ product complex.
    Bihani S; Das A; Prashar V; Ferrer JL; Hosur MV
    Proteins; 2009 Feb; 74(3):594-602. PubMed ID: 18704947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and conformational analysis of a novel series of HIV protease inhibitors.
    Baker CT; Salituro FG; Court JJ; Deininger DD; Kim EE; Li B; Novak PM; Rao BG; Pazhanisamy S; Schairer WC; Tung RD
    Bioorg Med Chem Lett; 1998 Dec; 8(24):3631-6. PubMed ID: 9934484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystal structures of highly constrained substrate and hydrolysis products bound to HIV-1 protease. Implications for the catalytic mechanism.
    Tyndall JD; Pattenden LK; Reid RC; Hu SH; Alewood D; Alewood PF; Walsh T; Fairlie DP; Martin JL
    Biochemistry; 2008 Mar; 47(12):3736-44. PubMed ID: 18311928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.